skip to main content

Acute Ischaemic Stroke – Extended Window Thrombectomy — SCE Neurology MCQ

Instant feedback + full explanation. One question, done properly.

HardCerebrovascular DiseaseAcute Ischaemic Stroke – Extended Window ThrombectomySCE Neurology

A woman with relapsing multiple sclerosis receives ocrelizumab and wishes to conceive. Assuming treatment is stopped, what minimum interval after her final infusion is specified by the current UK product information before she attempts conception?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — Continue effective contraception for four months after the final infusion

The current UK ocrelizumab SmPC advises women of childbearing potential to use contraception during treatment and for four months after the last infusion. This product-information interval is a minimum fetal-exposure precaution, not a complete pregnancy plan: in highly active disease, the timing of treatment interruption still needs individualised specialist discussion because relapse risk may alter the strategy. The one-, two-, three- and six-month choices do not match the current UK SmPC.

Reference: OCREVUS 300 mg concentrate UK summary of product characteristics (Current UK SmPC, updated 2026): https://www.medicines.org.uk/emc/product/8898/smpc; Association of British Neurologists 2024 guidance on multiple-sclerosis disease-modifying treatments (Published 2024; current ABN guidance): https://doi.org/10.1136/pn-2024-004228